Combined use of emapalumab and ruxolitinib in a patient with refractory hemophagocytic lymphohistiocytosis was safe and effective. Issue 7 (22nd March 2021) - Triebwasser, Michael P.; Barrett, David M.; Bassiri, Hamid; Bunin, Nancy; Elgarten, Caitlin; Freedman, Jason; Geera, Abdallah S.; Monos, Dimitri; Lambert, Michele P.; Olson, Timothy; Seif, Alix E.; Paessler, Michele; et al.